Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | PPARD | Q03181 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | FOS | P01100 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9781691 | 0.97 | LDHA (0.76) | LDHAALOX15ALOX12PPARDPPARA | |
| SCHEMBL18082680 | 0.97 | LDHA (0.76) | LDHAALOX15ALOX12PPARDPPARA | |
| SCHEMBL3175155 | 0.84 | FOS (0.69) | LDHAALOX15ALOX12MAPK1MMP1 | |
| SCHEMBL22108693 | 0.84 | FOS (0.69) | LDHAALOX15ALOX12MAPK1MMP1 | |
| SCHEMBL16913261 | 0.84 | LDHA (0.58) | LDHAALOX15ALOX12PPARDPPARA | |
| SCHEMBL16973674 | 0.84 | LDHA (0.66) | LDHAALOX15ALOX12MAPK1ALDH1A1 | |
| SCHEMBL10734796 | 0.84 | LDHA (0.66) | LDHAALOX15ALOX12PPARDPPARA | |
| SCHEMBL490731 | 0.83 | LDHA (1.00) | LDHAALOX15ALOX12MAPK1MMP1 | |
| SCHEMBL9518156 | 0.83 | MMP1 (0.58) | LDHAMMP1ALDH1A1NPC1HTT | |
| SCHEMBL15570321 | 0.83 | LDHA (0.56) | LDHAPPARDPPARAMMP1TUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8491929-B2 | Bioadhesive polymers | VAUNNEX INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110086095-A1 | Bioadhesive Polymers | Spherics, Inc (MA) | 2011-04-14 | — | — | US | disclosed |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1901720-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | Spherics, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008002471-A2 | EROSION-STABILIZED BIOADHESIVE POLYMERS FUNCTIONALIZED OR BLENDED WITH CATECHOL AND DERIVATIVES THEREOF | SPHERICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007002516-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002318-A2 | BIOADHESIVE POLYMERS | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086095-A1 | Bioadhesive Polymers | CD44, EPCAM, ABCG2 | LDHA 109/4885ALOX15 1971/4885ALOX12 1451/4885 |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | PARK7, SNCA, COMT | LDHA 560/4885ALOX15 317/4885ALOX12 544/4885 |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | LDHA 1644/4885ALOX15 1133/4885ALOX12 1699/4885 |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | LDHA 1644/4885ALOX15 1133/4885ALOX12 1699/4885 |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | LDHA 1644/4885ALOX15 1133/4885ALOX12 1699/4885 |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | LDHA 1644/4885ALOX15 1133/4885ALOX12 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.